| Renal Cell Carcinoma
Sutent vs Torisel
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Sutent vs Torisel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTorisel has a higher rate of injection site reactions vs Sutent based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Torisel but not Sutent, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sutent
Torisel
At A Glance
Oral
Daily
Multi-targeted RTK inhibitor
IV infusion
Once weekly
mTOR inhibitor
Indications
- Gastrointestinal Stromal Tumors
- Renal Cell Carcinoma
- Well Differentiated Pancreatic Endocrine Neoplasm
- Renal Cell Carcinoma
Dosing
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma 50 mg orally once daily on Schedule 4/2 (4 weeks on, 2 weeks off); adjuvant RCC limited to a maximum of nine 6-week cycles.
Well Differentiated Pancreatic Endocrine Neoplasm 37.5 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 25 mg administered as an IV infusion over 30-60 minutes once weekly; continue until disease progression or unacceptable toxicity.
Contraindications
—
- Bilirubin >1.5x ULN
Adverse Reactions
Most common (>=25%) Fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, thrombocytopenia.
Serious Hepatotoxicity, cardiovascular events, QT interval prolongation and Torsade de Pointes, hemorrhagic events, tumor lysis syndrome, thrombotic microangiopathy, proteinuria, dermatologic toxicities, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypoglycemia, osteonecrosis of the jaw, impaired wound healing.
Postmarketing Hemorrhage associated with thrombocytopenia, esophagitis, acalculous cholecystitis, hypersensitivity reactions including angioedema, serious infection, fistula formation, myopathy/rhabdomyolysis, renal impairment/failure, pulmonary embolism, pleural effusion, pyoderma gangrenosum, arterial aneurysms/dissections/rupture, arterial thromboembolic events.
Most common (>=30%) Rash, asthenia, mucositis, nausea, edema, anorexia
Serious Hypersensitivity/infusion reactions, hepatic impairment, hyperglycemia/glucose intolerance, infections, interstitial lung disease, hyperlipidemia, bowel perforation, renal failure, wound healing complications, intracerebral hemorrhage
Postmarketing Angioedema, rhabdomyolysis, Stevens-Johnson Syndrome, complex regional pain syndrome, pancreatitis, cholecystitis, cholelithiasis
Pharmacology
Sunitinib is a small-molecule inhibitor of multiple receptor tyrosine kinases (RTKs) including PDGFRalpha/beta, VEGFR1/2/3, KIT, FLT3, CSF-1R, and RET, which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer.
Temsirolimus is an mTOR inhibitor that binds to FKBP-12; the protein-drug complex inhibits mTOR activity, blocking phosphorylation of p70S6k and S6 ribosomal protein downstream in the PI3 kinase/AKT pathway, resulting in G1 growth arrest in tumor cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sutent
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Torisel
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Sutent
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Torisel
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Sutent
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Torisel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Sutent Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Renal Cell Carcinoma (RCC): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SutentView full Sutent profile
ToriselView full Torisel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.